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ABSTRACT
Human germ cell tumors (GCTs) may have variable histology and
clinical behavior, depending on factors such as sex of the patient, age at
clinical diagnosis, and anatomical site of the tumor. Some types of GCT,
i.e., the seminomas/germinomas/dysgerminomas and embryonal carcino-
mas (the stem cell component of nonseminomas), have pluripotent poten-
tial, which is demonstrated by their capacity to differentiate into somatic
and/or extraembryonic elements. Although embryonal carcinoma cells are
intrinsically pluripotent, seminoma/germinoma/dysgerminoma cells, as
well as their precursor carcinoma in situ/gonadoblastoma cells, have the
phenotype of early germ cells that can be activated to pluripotency. The
other types of GCT (teratomas and yolk sac tumors of infants and
newborn, dermoid cyst of the ovary, and spermatocytic seminoma of
elderly) are composed of (fully) differentiated tissues and lack the appear-
ance of undifferentiated and pluripotent stem cells. OCT3/4, a transcrip-
tion factor also known as OTF3 and POU5F1, is involved in regulation of
pluripotency during normal development and is detectable in embryonic
stem and germ cells. We analyzed the presence of POU5F1 in GCT and
other tumor types using immunohistochemistry. The protein was consis-
tently detected in carcinoma in situ/gonadoblastoma, seminomas/germi-
noma/dysgerminoma, and embryonal carcinoma but not in the various
types of differentiated nonseminomas. Multitumor tissue microarray anal-
ysis covering >100 different tumor categories and 3600 individual cancers
verified that POU5F1 expression is specific for particular subtypes of
GCT of adults. No protein was observed in GCT of newborn and infants,
spermatocytic seminomas, and the various tumors of nongerm cell origin.
In addition, no difference in staining pattern was found in chemosensitive
and chemoresistant GCT of adults. These results indicate preservation of
the link between POU5F1 and pluripotency, as reported during normal
development, after malignant transformation. Therefore, POU5F1 immu-
nohistochemistry is an informative diagnostic tool for pluripotent GCT
and offers new insights into the histological heterogeneity of this cancer.
INTRODUCTION
oct3/4, also known as otf3 or pou5f1, is a member of the POU
family of transcription factors, which is expressed in pluripotent
mouse and human embryonic stem and germ cells, including PGCs4
(1–6). Expression of this gene is down-regulated during differentia-
tion (7). Furthermore, knocking out the pou5f1 gene in mice causes
early lethality because of lack of inner cell mass formation (8) because
pou5f1 is critical for self-renewal of embryonic stem cells (9). Inter-
estingly, pou5fl has been linked to the capacity of proper outgrowth of
somatic cell clones (10). During human development, expression of
POU5F1 is found at least until the blastocyst stage (11) in which it is
involved in gene expression regulation. The protein activates tran-
scription via octamer motifs located distally or proximally from
transcriptional start sites (12). POU5F1 binding sites have been iden-
tified in various genes, including fibroblast growth factor 4 and the
1.5-kb alternative promoter of the platelet-derived growth factor 
receptor (13). The data indicate that pou5f1/POU5F1 functions as a
master switch in differentiation by regulating cells that have, or can
develop, pluripotent potential.
We have previously demonstrated that POU5F1 transcripts are
found in a specific set of human testicular GCT of adolescents and
young adults (TGCT): the seminomas and embryonal carcinomas
(14). In addition, the precursor lesions of TGCT, known as CIS (15),
also express POU5F1 (14). These lesions are composed of cells that
are considered to be the malignant counterpart of an embryonic germ
cell, most likely a PGC (15–17). Interestingly, these cell types are in
principle pluripotent or even multipotent (Ref. 18, for review). In
contrast, no expression was found in the differentiated components of
nonseminomas, i.e., teratomas, yolk sac tumors, and choriocarcino-
mas (14). Indeed, expression of POU5F1 has been reported in em-
bryonal carcinoma cells lines, and down-regulation of expression is
found upon differentiation (4, 13).
In contrast to our finding of a specific expression pattern of
POU5F1 in TGCT, expression of this gene has recently been reported
in nonmalignant adult human tissues (19), as well as in a number of
carcinoma cell lines (20). This latter finding was interpreted as the
result of aberrant reactivation of embryonic genes during the process
of malignant transformation. However, the conclusion that POU5F1
is expressed in these cells was based solely on reverse transcription-
PCR results, which can be misleading because of the presence of
multiple POU5F1 pseudogenes (Refs. 14, 19, 21, own unpublished
observations). We are not aware of any previous studies reporting
analysis of POU5F1 protein expression in normal and malignant
human tissues to clarify whether the mRNA is translated to functional
POU5F1 protein. Therefore, an extensive immunohistochemical
screening for POU5F1 protein expression was done in various types
of GCT at different sites and in a set of 3600 tumors of 100
different types using multitumor tissue microarrays. POU5F1 immu-
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noreactivity was detected only in cells of CIS/gonadoblastoma, sem-
inoma/germinoma/dysgerminoma, and embryonal carcinoma. These
results convincingly demonstrate that the presence of POU5F1 protein
is related to pluripotent capacity of human GCT and that reactivation
of its expression is not a common mechanism in cancer. Conclusively,
POU5F1 is a distinctive immunohistochemical marker to identify
tumor cells resembling embryonic/primordial germ and embryonic
stem cells.
MATERIALS AND METHODS
Sample Handling and Characterization. The (T)GCT not included in the
tissue arrays were collected in the southwestern part of the Netherlands in
collaboration with urologists and pathologists. Representative parts of the
tumor (and adjacent tissue, if available) were snap frozen in liquid nitrogen and
were fixed in 10% formalin for paraffin embedding. Tumors were diagnosed
according to the WHO classification (22), as previously described (23), sup-
ported by immunohistochemistry using antibodies directed against germ cell/
placental alkaline phosphatase, -feto protein, human chorionic gonadotropin,
the stem cell factor receptor c-KIT, and cytokeratin (CAM5.2). The testicular
tumors included 35 seminomas, 50 nonseminomas [with 14 embryonal carci-
noma components, 21 teratoma components (6 mature, 5 immature, and 10
mixed), 18 yolk sac tumor components, and 5 choriocarcinoma components],
and 10 spermatocytic seminomas. In addition, CIS containing testicular pa-
renchyma (n  16, including both adjacent to seminoma and nonseminoma)
and embryonic testes of different developmental stages, i.e., from 17 to 40
weeks and 28 weeks postpartum, were included. These latter samples have
been reported before (24). Moreover, 3 gonadoblastomas, found in dysgenetic
gonads, of which 2 also contained dysgerminoma, as well as 4 GCT of the
midline of the brain of adults (including 1 germinoma, 1 embryonal carcinoma,
and 2 mixed differentiated nonseminomas) were included. To investigate
possible difference in presence of POU5F1 between chemotherapy-sensitive
and -resistant GCT, a series of 34 patients with known clinical course,
including 12 high-risk patients that were relapse-free after high-dose chemo-
therapy and 22 refractory cases, were investigated. Part of this series has been
reported before (25, 26). The clinical parameters are indicated in Table 1.
Patients were considered refractory when progression or relapse occurred
despite adequate initial and salvage treatment, including high-dose chemother-
apy with autologous stem-cell transplantation.
To expand the series of both GCT and non-GCT, three different multitumor
tissue microarrays were investigated. One was generated at the Department of
Pathology of the University of Basel (Basel, Switzerland), and included 3273
interpretable individual tumors of 100 different types, represented on seven
different slides (Table 2 and Fig. 2). The second was generated at the Division
of Pediatric Pathology of the Johns Hopkins Medical Institution (Baltimore,
MD) and included 84 (T)GCT of newborn, infants, and adolescents (Table 3),
represented on four different slides. Both arrays contained various positive and
negative controls. The third array, generated at the Department of Pathology,
Erasmus Medical Center (GE Rotterdam, the Netherlands), included 48 esoph-
agus tumors and 100 prostate cancers (50 progressing and 50 nonprogressing),
as well as benign prostatic hypertrophy (n  18). The result of this latter array
is included in Table 1.
Immunohistochemistry. Immunohistochemistry with anti-POU5F1 anti-
bodies was performed on paraffin-embedded tissue sections of 3-m thickness.
The sections were incubated overnight at 4°C with a polyclonal goat anti-
POU5F1 antibody (C20, sc 8629; Santa Cruz Biotechnology, Santa Cruz, CA),
directed toward the COOH terminus of the protein, diluted 1:8000 (final
concentration, 0.025 g/ml). Subsequently, a biotinylated horse-antigoat sec-
ondary antibody was applied to the sections, and the bound antibody complex
was visualized using the horseradish peroxidase avidin-biotin complex
method. Double fluorescence staining was performed using the polyclonal
goat-anti-POU5Fl antibody and a monoclonal mouse-anti-c-KIT antibody (fi-
nal concentration 2 g/ml; Neomarkers, Fremont, CA) on frozen tissue sec-
tions. c-KIT is a known marker for CIS and seminomas (27). Secondary
antibodies were labeled with FITC and CY3 (Dako Diagnostics, Glostrup,
Denmark, and Jackson Immunoresearch, West Grove, PA, with a final con-
centration of 5 g/ml), respectively. The stainings were also performed sep-
arately. Every experiment was accompanied by appropriate positive and neg-
ative (without primary antibody) controls.
Cell Culture. The human cell lines Tera2 (28), 2102Ep (29), and NCCIT
(30), all nonseminoma derived, were cultured and split under conventional
conditions (37°C, 5% CO2). Cell lines were cultured until 80% confluency, and
differentiation was induced with retinoic acid as described previously (30).
Immunohistochemistry was performed on cytospin preparations as described
above.
RESULTS
POU5F1 Immunohistochemistry on TGCT. On the basis of
mRNA analysis (14), we expected that POU5F1 protein is present in
specific different histological subtypes of TGCT. We first analyzed
the presence of POU5F1 by immunohistochemistry on a series of
TGCT of various histological types. Representative images of repre-
sentative stainings are shown in Fig. 1. All tumor cells of seminomas
and embryonal carcinomas showed a nuclear staining (Fig. 1, A and
B), whereas all nontumor cells were negative. A similar pattern of
staining was found in the gonadoblastomas, dysgerminomas and ger-
minomas, and embryonal carcinomas of the brain (see also below). In
contrast, all teratomas, both mature and immature, choriocarcinomas,
and yolk sac tumors were negative (Fig. 1, C–E), as were the differ-
entiated nonseminomas of the brain (data not shown). The staining
intensity in the positive cases varied between moderate and high.
None of the spermatocytic seminomas showed a positive staining
(Fig. 1F). We also tested a series of CIS containing testicular paren-
chyma samples, both adjacent to seminoma and nonseminoma. All
CIS cells, identified by a double staining for c-KIT, irrespective of the
histology of the invasive tumor, were positive for POU5F1 (Fig. 1G
and inset). In contrast, no protein could be detected in any stage of
spermatogenesis (see below). This makes POU5F1 one of the most
informative immunohistochemical markers to identify CIS cells that
our laboratory has tested.
To investigate whether a difference in presence of POU5F1 exists
between chemosensitive and chemoresistant GCT, immunohisto-
chemistry was done on a well-characterized series of GCT with
known clinical outcome (Refs. 25, 26 and Table 2). The results
Table 1 Clinical parameters of the patients with chemosensitive and
chemoresistant GCT
Sensitive Resistant
Nos. of cases 12 22
Median age in years (range) 28 (20–47) 29 (17–56)
Histologya
Seminoma 1 1
Nonseminoma 11 21
Stage at diagnosis (UICCb)
I 0 3
II 0 7
III 12 12
Initial treatment after surgery
Surveillance 0 2
Chemotherapy 12 20
Follow-up (months)
Median (range) 51 (14–69) 39 (11–180)
Relapse free survival (months)
Median (range) NR 7.1 (0–150)
Response to initial treatment
Complete remission 8 5
Partial remission, marker  4 8
Partial remission, marker  0 3
Progressive disease 0 3
Unknown 0 3
No. of salvage regiments
Median (range) 0 3 (1–9)
a For the POU5F1 immunostaining all seminoma, embryonal carcinoma, and CIS
components of both the sensitive and resistant tumors (3 and 2; 6 and 8; and 4 and 6,
respectively) are positive, whereas all differentiated nonseminoma components are neg-
ative.
b UICC, International Union Against Cancer; NR, not reached.
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Table 2 Results of tissue array immunohistochemistry of 3439 individual tumors of 100 different types for POU5F1
The organ (in alphabetic order), tumor type, number of cases studied, and positive findings are indicated
Organ Tumor Subgroup n Positive
Adrenal gland Carcinoma Adeno- 19 0
Anus Carcinoma Squamous 3 0
Brain Gliobl. multif./astrocytoma/ 46/35 0
oligodendroglioma/meningioma/ 24/46 0
PNET/ependymoma/ 17/9 0
gangioneuroma/ 7 0
medulloblastoma/estioneuroblastoma/ 4/2 0
opticus glioma/cranioph.a 1/8 0
Carotid body Glomus tumor 11 0
Cervix Carcinoma Squamous/CIS/adeno 37/7/4 0
Colon Adenoma Tubular and villous 134 0
Carcinoma Adeno- 47 0
Endometrium Carcinoma Adeno- 61 0
Sarcoma Endometrial stromal sarcoma 3 0
Esophagus Carcinoma Squamous/adeno 21/116 0
Gall bladder Carcinoma Adeno- 23 0
Glomus tumor 11 0
Kidney Carcinoma Clear cell/papillary 50/45 1/0
Chromophobic 13 0
Oncocytoma 7 0
Larynx Carcinioma Squamous 46 0
Liver Carcinoma Hepatocellular 41 0
Lung Carcinoma Adeno-/squamous/ 48/50 0/1
large cell/small cell 47/41 1/0
Lymph nodes Lymphoma Hodgkin’s 50 0
Non-Hodgkin’s high/low grade 69 0
MALT 42 0
Breast Carcinoma Lobular/ductal 42/46 0
Med./muc./tub. 27/23/26 0
Cribriform/apocrine 5/3 0
Phylloidees tumor 13 0
Mouth Carcinoma Squamous 57 0
Ovary Carcinoma Endometroid/serous mucinous 49/48/20 0
Brenner/mixed Mu¨llerian tumor 9/6 0
Granulosa cell 7 0
Dysgerminoma 2 2
Gonadoblastoma 1 1
Pancreas Carcinoma Adeno- 47 0
Paraganglia Paraganglioma 10 0
Parathyroid Carcinoma Adeno- 20 0
Parotid gland Carcinoma Mixed 15 0
Acinic cell/mucoepithelial 5/6 0
Phaeochrom. 26 0
Penis Carcinoma Squamous 43 0
Prostate Carcinoma Adeno-, horm. (non-)refract. 200 0
PIN/BPH 24/18 0
(Small) salivary gland Pleom. adenoma 49 0
Lymphoep. lesion 5 0
Carcinoma Adenoid cystic 43 0
Acinic cell 36 0
Adenolymph. 30 0
Skin Carcinoma Squamous/basal 81/37 0
Melanoma 44 0
Merkel cell tumor 6 0
Benign Hemangioblastoma 8 0
Nevus 38 0
Appendix tumors 25 0
(Small) intestine Carcinoma Adeno- 17 0
GIST 14 0
Stomach Carcinoma Intestinal/diffuse 44/23 0
Soft tissue Benign Lipoma/fibrous histiocytoma/Schwann/ 15/58/35 0
neurofibroma/leiomyoblastoma/ 31/7 0
giant cell tumors of tendon sheet/ 29/ 0
hemangioma 17 0
Intermediate Haemangiopericytoma 8 0
Dermatofibrosarcoma protuberans 2 0
Malignant Kaposi/liposarcoma 25/26 0
Angiomyolipo./malign. Schwann. 1/8 0
Rhabdomyosarcoma/synovial sarcoma 13/3 0
Angios./fibros./alv. soft part sarc. 4/6/1 0
Epithelioid sarcoma 2 0
Testis Seminoma/nonseminoma 49/47 49/33b
Adenomatoid tumor 10 0
Thyroid Carcinoma Foll./papill./med. 42/48/36 0
Thymus Thymoma 23 0
Urinary bladder Carcinoma TCC 101 0
Small cell/squamous/adeno- 3/5/4 0
Sarcoma 7 0
Uterus Myoma 107 0
Vagina Carcinoma Squamous 5 0
Vulva Carcinoma Squamous 37 0
Various Carcinoid 48 0
Adenomatoid tumor 10 0
Mesothelioma 23 0
Controlsc 30 0
a Gliob. multif., glioblastoma multiforme; PNET, primitive neuro-ectodermal tumor; cranioph, craniopharyngioma; CIS, carcinoma in situ; MALT, mucosa associated lymphoid
tissue; med, medullar; muc, mucinous; tub, tubular; horm (non-)refract, hormonal (non)refractory; angiomyolipo., angiomyoliposarcoma; malign. Schwann., malignant Schwannoma;
anglo., angiosarcoma; fibros., fibrosarcoma; alv. soft part sarc., alveolar soft part sarcoma; foll., follical.
b If containing seminoma in case of combined tumors or embryonal carcinoma elements.
c Included in all seven slides: skin (n  4); lymph node (n  2); heart (n  2); skeletal muscle (n  2); smooth muscle (n  2); myometrium (n  2); thyroid gland (n  2); liver
(n  2); kidney cortex (n  2); prostate (n  2); testis (n  2); submand. gland (n  2); proliferative endometrium (n  2); gray matter cerebrum (n  2).
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indicate that the staining pattern is determined by histology, i.e.,
positive in CIS, seminoma and nonseminoma, irrespective of sensi-
tivity to chemotherapy.
Immunohistochemistry for POU5F1 in Normal Spermatogene-
sis and Embryonic Germ Cells. Although POU5F1 could be de-
tected by immunohistochemistry in CIS cells and cells of seminoma
and embryonal carcinoma (see above), no staining was observed in
seminiferous tubules containing normal spermatogenesis (Fig. 1G),
neither on frozen nor formalin-fixed, paraffin-embedded tissue sec-
tions. In contrast, embryonic germ cells in embryos and fetuses were
occasionally positive. The highest number and most intensely stained
germ cells were found in gonads between week 17 and 24 of gesta-
tional age (Fig. 1H and see below). Earlier stages of development
were not available for investigation. Only sporadic positive cells were
identified in the samples obtained from developmental stages weeks
28, 35 and 37, whereas no staining was found in samples of 38 and 40
weeks gestational age and after birth. Germ cells are present in these
samples, as identified by staining for various markers, including
c-KIT and VASA (24, 31). These data indicate that POU5F1 is
present in germ cells at least from the 17th to 37th week of gestational
age, after which the protein is no longer detectable by immunohisto-
chemistry.
POU5F1 in Undifferentiated and Differentiated Cells of TGCT-
derived Cell Lines. In the nonseminomatous TGCT-derived cell line
Tera2, expression of the POU5F1 is only observed in undifferentiated
cells, whereas induction of differentiation of embryonal carcinoma
cells with retinoic acid results in down-regulation of POU5F1 expres-
sion. The potential of Tera2 cells to differentiate has been described
before (4, 14). Here, we confirm this finding on the protein level by
immunohistochemistry (Fig. 1I, left and right panel). In contrast, both
the cell lines NCCIT and 2102Ep showed POU5F1 expression and
protein before and induction with retinoic acid differentiation (data
not shown). This is in accordance to the finding that these cell lines,
in contrast to Tera2, do not show complete differentiation after ex-
posure to retinoic acid (28, 30).
POU5F1 Immunohistochemistry on Multitumor Tissue Mi-
croarrays. To investigate whether POU5F1 protein can be detected
in other tumors than GCT, we performed immunohistochemistry
using the same antibody on three different multitumor tissue microar-
rays. One contained a large series of tumors of different origin (Table
1), one of the other contained specifically prostate and esophageal
carcinomas (of which the results are also included in Table 1), and one
contained mainly GCT of newborn and infants (Table 3). None of the
control tissues, both adult and embryonal (with one exception, see
below), included in the arrays showed positive staining for POU5F1.
Of the 3439 tumors (from the first arrays), all testicular seminomas
and nonseminomas (containing either a seminoma or an embryonal
carcinoma component), as well as two dysgerminomas and one go-
nadoblastoma were positive, confirming the results presented above.
Representative examples of the first arrays are shown in Fig. 2. In
addition, one clear cell carcinoma of the kidney and two lung carci-
nomas (one squamous cell carcinoma and one undifferentiated large
cell carcinoma) were positive, suggesting that POU5F1 protein can be
found in a small percentage (1–2%) of other tumors.
The multitumor tissue microarray of the (T)GCT confirmed the
specificity of the POU5F1 immunohistochemistry for the histological
types CIS/gonadoblastoma, seminoma/dysgerminoma, and embryonal
carcinoma, as described above (Table 3). None of the immature and
mature teratomas and yolk sac tumors showed a positive staining.
Again, embryonic germ cells, included as arrays in the array, were
also positive (data not shown). These data establish POU5F1 as highly
specific marker for normal and malignant embryonic germ cells and
embryonic stem cells, both in precursor (CIS) lesions and invasive
tumors.
DISCUSSION
Human GCTs comprise a heterogeneous group of neoplasms,
which are predominantly found along the midline of the body. This
localization can be explained by the migration route of the PGC
during embryogenesis from the yolk sac to the genital ridge (32). The
histology and clinical behavior of the various types of GCT depends
on the sex of the patient, the age at clinical diagnosis, the anatomical
location, and histology of the tumor (Ref. 33 for review). Overall, four
different entities can be distinguished: (a) the teratomas and yolk sac
tumors of newborn and infants; (b) the seminomas/dysgerminomas/
germinomas and nonseminomas of the gonads (both ovary and testis,
and dysgenetic gonad), anterior mediastinum, and midline of the
brain; (c) the dermoid cyst (mature cystic teratoma) of the ovary; and
(d) the spermatocytic seminoma of the elderly testis. From a biolog-
ical point of view, the pluripotent tumors (entity b) are the most
intriguing. Histologically, they are subdivided into seminomas
(known as dysgerminoma when identified in the ovary and dysgenetic
gonad, and germinoma when arising in extragonadal sites) and non-
seminomas (Ref. 34 for review). The seminoma-like tumors are
composed of cells with a similar morphology as CIS cells. The
nonseminomas can contain different histological elements, including
embryonal carcinoma as the stem cell component, teratoma (repre-
senting somatic differentiation), yolk sac tumor, and choriocarcinoma
(representing extraembryonic differentiation). The occurrence of em-
bryoid bodies in nonseminomas (22), as well as certain patterns of
Table 3 Results of the multitissue microarray immunohistochemistry on 84 germ cell
tumors of predominantly newborn, infants, and adolescents for POU5F1
The histology and anatomical localization of the tumor, sex of the patient, number of
studied cases (n), age at clinical presentation and number of positive findings are
indicated.
Histology Sexa Anat. Local. n Age (yr) Positive
Teratoma Total: 25 0
Mature M Sacral 2 0/1 0
F “ 2 0/0 0
M Nervous system 1 6 0
F Gonad 2 15/34 0
M “ 1 0.3 0
Immature F Sacral 3 0/0/0 0
M “ 1 0.3 0
F Gonad 11 5/6/8/10/10/11/12/
12/13/15/?b
0
M “ 1 0.8 0
? ? 1 ? 0
Yolk sac tumor Total: 33
F Sacral 6 0.2/1/1/2/2.6/5 0
M “ 1 1.5 0
? “ 6 0/0.5/?/?/?/? 0
M Gonad 10 0.7/0.7/1.3/1.3/1.9/
2/2/2.8/3/4
0
F “ 9 7/8/9/10/10/13/ 0
18/20/24
Gonadoblastoma/
Dysgerminoma
D Gonad 1 ? 1
Dysgerminoma F Gonad 11 12/12/12/17/18/14/
14/?/?/?/?
1
Dysgerminoma/
Nonseminoma
F Gonad 1 12 1
Seminoma M Gonad 4 27/30/41/? 4
Mixed GCTc M Gonad 4 27/28/29/? 4d
Nonseminoma M Gonad 5 23/?/?/? 5e
Controlsf M/F 30 0
a M, male; F, female; ?, unknown; D, dysgenetic gonad.
b ?, unknown.
c Germ cell tumor.
d When containing either a seminoma of embryonal carcinoma component.
e When containing an embryonal carcinoma component.
f POC (n  9); fetal kidney (n  4), fetal ovary (n  1), fetal uterus (n  2), Wilms’
tumor (n  2), hepatoblastoma (n  3), embryonal neuroblastoma (n  5), testis (n  3),
MMMT (n  1).
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gene expression, including POU5F1 (4, 13, 14, 35–38), illustrates the
similarities between developmental patterns in the embryo and non-
seminomas. This study aimed at a further understanding of the nature
of the pluripotent (T)GCT compared with the other types of GCT and
tumors of nongerm cell origin.
Here, we convincingly show that testicular CIS, seminoma, and
embryonal carcinoma cells are consistently positive for POU5F1,
irrespective of chemosensitivity or chemoresistance. Gonadoblasto-
mas and associated dysgerminomas, as well as germinomas and
embryonal carcinomas of the midline of the brain, showed a similar
pattern. In contrast, none of the differentiated nonseminomatous de-
rivatives (teratoma, yolk sac tumor, and choriocarcinoma) stained
positive, irrespective of anatomical localization. This suggests that
loss of protein expression is because of down-regulation of gene
expression upon differentiation/maturation. These data are in accord-
ance with earlier findings in mice, indicating that pou5f1 is indeed a
marker for embryonic stem cells and germ cells (1–3) and that
expression is lost upon additional differentiation and maturation (7).
The fact that we observed a homogeneously positive staining for
POU5F1 in the embryonal carcinoma components of both pure and
mixed nonseminomas (and representative cell lines) supports the
model that the encoded protein is crucial but not sufficient for pluri-
potency. This has also been implied by the recent finding that
POU5F1 overexpression had no effect on HeLa cells (39). Appar-
ently, particular auxiliary proteins are needed. In accordance with the
histology-dependent pattern of POU5F1 staining, both mature and
immature teratomas, as well as the yolk sac tumors of newborn and
infants, are negative. This is also true for the spermatocytic semino-
mas. Both tumor types have a different pathogenesis from TGCT (22,
24, 40–47). The absence of POU5F1 in these tumors is in agreement
with their inability to generate pluripotent stem cells.
Our findings within in vivo tumor samples and representative cell
lines are concordant with previous findings in mice (8, 9), showing
that pou5f1 is expressed in pluripotent cells and is down-regulated
upon differentiation. Therefore, we conclude that POU5F1 is involved
in regulation of differentiation of human cells in line with a report on
human embryos (6). No POU5F1 was detectable in adult testicular
samples with normal spermatogenesis by immunohistochemistry,
which is consistent with findings in mice using fluorescent protein-
tagged pou5f1 expression analysis (48). However, a positive staining
by immunohistochemistry has been reported in mouse spermatogonia
A (7). This difference might be because of sensitivity differences of
the methods applied and/or differences in protein level. The finding of
POU5F1 in human embryonic germ cells and the down-regulation
of expression before spermatogonia A formation supports an embry-
onic initiation of the pathogenesis of TGCT (15, 16, 27, 49–52).
We did not find POU5F1 protein in any of the differentiated
components of nonseminomas or in the majority (99.9%) of 3340
nongerm cell tumors. This indicates that reactivation of POU5F1
expression and translation, as previously suggested based on cell line
Fig. 1. Visualization of POU5F1 protein by immunohistochemistry on formalin-fixed, paraffin-embedded tissue sections of a seminoma (A); pure embryonal carcinoma (B); mixed
embryonal carcinoma and teratoma (C); mixed embryonal carcinoma and choriocarcinoma (D); mixed embryonal carcinoma and yolk sac tumor (E); spermatocytic seminoma (F);
testicular parenchyma containing seminiferous tubules with normal spermatogenesis and CIS cells. Inset shows a seminiferous tubules with CIS cells double stained for c-KIT (green)
and POU5F1 (red) (G); an embryonic testis of 21 weeks of gestation (H); cytospins of Tera2 cells before (left panel) and after (right panel) exposure to retinoic acid, inducing
differentiation, and resulting in loss of POU5F1 (I).
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data (20), is not a frequent finding in cancer. The positive tumors were
one kidney carcinoma (of 50 clear cell carcinomas) and two lung
carcinomas (1 of 50 squamous and 1 of 47 large cell carcinomas
analyzed). We do not currently have any plausible biological expla-
nation for POU5F1 expression in these tumor types. Nevertheless,
rare occurrence of POU5F1 immunoreactivity in kidney and lung
must be kept in mind when performing immunohistochemistry for
POU5F1 to demonstrate a pluripotent GCT in these organs. We think
that the discrepancy between our study and the previous report sug-
gesting reactivation of POU5F1 occurring as part of the malignant
transformation process (20) can be attributable to the different tech-
niques used. The mRNA expression analyses by Monk and Holding
(20) were performed using reverse transcription-PCR with primers
that may amplify both POU5F1 and different intron-less POU5F1-
related sequences (unpublished observations).
In conclusion, this study demonstrates the usefulness of POU5F1
immunohistochemistry to support that TGCT originate from PGC and
have pluripotent potential. However, POU5F1 is also present in nul-
lipotent embryonal carcinoma and thus does not predict whether an
embryonal carcinoma is able to generate various lineages of differ-
entiation. Overall, POU5F1 is a highly specific immunohistochemical
marker to confirm the diagnosis of CIS/gonadoblastoma, seminoma/
dysgerminoma, and embryonal carcinoma. In addition, these data
support the hypothesis that (T)GCT are excellent models to study the
molecular mechanisms of pluripotency and differentiation, and there-
fore, a deeper understanding of these mechanism might also reflect
into the rapidly evolving field of stem cell biology. Conversely,
advances in the rapid evolving field of stem cell biology regarding the
control of differentiation might also provide innovative therapeutic
alternatives in (T)GCT in the future.
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